Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Memantine Shows Small But Consistent Effect In Alzheimer’s – Cmte.

Executive Summary

Forest memantine (Namenda) has a small but consistent effect in patients with moderate to severe Alzheimer's dementia, FDA's Peripheral & Central Nervous System Drugs Advisory Committee concluded Sept. 25

You may also be interested in...



Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December

Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent

Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December

Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent

Forest Memantine Plans Include Expanded Mild Alzheimer’s Indication

Forest plans to expand the indication of its Alzheimer's drug Namenda (memantine) to include patients with mild dementia if study results expected at the end of the year are positive

Related Content

UsernamePublicRestriction

Register

PS042535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel